Table 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Christian Rolfo(Icahn School of Medicine at Mount Sinai), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Christopher Stroh(Universität Hamburg), Aurora O’Brate(Scripps Research Institute), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Rolf Bruns(Inserm), Christoph Menzel(Merck KGaA, Darmstadt (Germany)), Andreas Johne(Merck KGaA, Darmstadt (Germany))
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations
|Journal of Clinical Oncology|2011|689